Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration
BACKGROUND AND OBJECTIVE: Macular atrophy (MA) contributes to declining vision during prolonged anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) so greater understanding of its incidence, evolution, and impact on visual acuity is merited
Bibliographische Detailangaben
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 10 vom: 17. Okt., Seite 546-552
|
|---|
| 1. Verfasser: |
Richardson, Quintin R
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Zhang, Youning,
Deiner, Michael S,
Wang, Suling T,
Bhisitkul, Jonah M,
Arnold, Benjamin F,
Bhisitkul, Robert B |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2022
|
|---|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina
|
|---|
| Schlagworte: | Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Angiogenesis Inhibitors
Endothelial Growth Factors
Vascular Endothelial Growth Factor A
Ranibizumab
ZL1R02VT79 |
|---|